-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Two New Products of the Company Receive Drug Production Registration Approvals
Category:
发布时间：2019-01-08
【概要描述】
After five years of development by the company, the ambroxol hydrochloride injection in three-in-one polypropylene (PP) ampoule packaging—available in 4 mL: 30 mg, 2 mL: 15 mg, and 1 mL: 7.5 mg—and the tirofiban hydrochloride sodium chloride injection in glass vial packaging—available in 250 mL and 100 mL—have both obtained drug production registration approvals from the National Medical Products Administration.
Recently, the company’s five-year development of a three-in-one polypropylene (PP) ampoule packaging for ambroxol hydrochloride injection—available in 4 mL: 30 mg, 2 mL: 15 mg, and 1 mL: 7.5 mg—and glass-bottle packaging for tirofiban hydrochloride sodium chloride injection—in 250 mL and 100 mL sizes—has been granted drug production registration approval by the National Medical Products Administration.
According to the company’s Pharmaceutical Research Institute, ambroxol hydrochloride injection is classified as a Category 6 original chemical drug and is indicated for the treatment of respiratory diseases. Tirofiban hydrochloride sodium chloride injection is also classified as a Category 6 original chemical drug and is a cardiovascular medication used in the management of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091